Skip to Content

Taclonex Approval History

  • FDA approved: Yes (First approved January 9th, 2006)
  • Brand name: Taclonex
  • Generic name: calcipotriene and betamethasone dipropionate
  • Dosage form: Ointment
  • Company: LEO Pharma
  • Treatment for: Psoriasis

Taclonex is a topical ointment containing a combination of calcipotriene and betamethasone for the treatment of psoriasis vulgaris in adults.

Development History and FDA Approval Process for Taclonex

May 12, 2008Approval FDA Approves Taclonex Scalp - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis
Jan 11, 2006Approval FDA Approves Taclonex - Once Daily Therapy for Treatment of Psoriasis

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.